Long-term health-related quality of life improvements among patients treated with lurasidone: results from the open-label extension of a switch trial in schizophrenia

Table 4 Mean changes in PETiT total and domain scores by responder status

		Responders			Non-responders
		Core Study BL	Extension Study BL	Extension Study EP	Core Study BL	Extension Study BL	Extension Study EP
PETiT Total Score	N	31^a	31^b	24^c	110^a	108^b	71^c
	Mean Score (SD)	32.5 (8.4)	41.0 (10.4)	40.5 (9.6)	35.6 (9.5)	39.1 (8.4)	38.6 (8.8)
	Change from Core BL (SD)	--	8.4 (8.5)	8.0 (6.5)	--	3.5 (7.4)	4.1 (7.1)
	p-value (between group)	--	0.010*	0.152**	--	--	--
Adherence-related Attitude Domain Score	Mean Score (SD)	8.1 (2.2)	10.1 (2.1)	10.0 (1.7)	8.8 (2.2)	9.7 (1.8)	9.6 (1.9)
	Change from Core BL (SD)	--	2.0 (2.2)	2.0 (2.2)	--	0.9 (2.3)	1.0 (2.5)
	p-value (between group)	--	0.051*	0.318ˣ**	--	--	--
Psychosocial Functioning Domain Score	Mean Score (SD)	24.5 (7.3)	30.9 (8.8)	30.6 (8.5)	26.8 (8.2)	29.4 (7.5)	29.0 (7.8)
	Change from Core BL (SD)	--	6.4 (7.0)	6.0 (5.5)	--	2.5 (6.1)	3.0 (5.7)
	p-value (between group)	--	0.014*	0.220**	--	--	--

Note: Extension study BL = 6-week follow-up; extension study EP = end of additional 24 weeks of treatment
Abbreviations: BL baseline, EP endpoint, PETiT Personal Evaluation of Transitions in Treatment, SD standard deviation
^aNumber of patients with PETiT total and domain scores at core study baseline
^bNumber of patients with PETiT total and domain scores at both core study baseline and extension study baseline
^cNumber of patients with PETiT total and domain scores at both core study baseline and extension study endpoint
*P-value comparing mean changes in PETiT total/domain scores from extension study baseline to core study baseline between responders and non-responders
**P-value comparing mean changes in PETiT total/domain scores from extension study endpoint to core study baseline between responders and non-responders

ISSN: 1471-244X